Adaptive Biotechnologies Corporation, a Seattle, WA-based company that leverages next generation sequencing to profile T-cell and B-cell receptors, acquired Sequenta, Inc., a South San Francisco, California-based developer of clinical diagnostics using immunosequencing.
The amount of the transaction was not disclosed.
Led by Chad Robins, CEO, Adaptive leverages NGS to profile T-cell and B-cell Receptors enabling in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.
Founded in 2008, Sequenta markets a laboratory developed test for use in the diagnosis and monitoring of minimal residual disease in blood cancers.
The companies will integrate teams across senior management, R&D, bioinformatics, and sales. Sequenta founders Tom Willis and Malek Faham will join Adaptive’s senior leadership team reporting to Chad Robins, who will remain CEO of the combined company. Dr. Willis and Dr. John Stuelpnagel, Sequenta’s Chairman, Illumina co-founder, and Chairman of Ariosa Diagnostics, also will join Adaptive’s board of directors.